Who are Gaba's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Alphagan, Alphagan, Iopidine, Cortone, Bupivacaine Hydrochloride And Epinephrine, Epipen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aminobutyric-acid.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Gaba — Competitive Intelligence Brief

Gaba (aminobutyric acid) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: alpha-Adrenergic Agonist [EPC]. Area: Metabolic.

marketed alpha-Adrenergic Agonist [EPC] Platelet glycoprotein VI, Sodium- and chloride-dependent GABA transporter 3, Gamma-aminobutyric acid receptor subunit rho-1 Metabolic Live · refreshed every 30 min

Target snapshot

Gaba (aminobutyric acid).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gaba TARGET	aminobutyric acid		marketed	alpha-Adrenergic Agonist [EPC]	Platelet glycoprotein VI, Sodium- and chloride-dependent GABA transporter 3, Gamma-aminobutyric acid receptor subunit rho-1
Alphagan	BRIMONIDINE TARTRATE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Alphagan	BRIMONIDINE	Senju Pharmaceutical Co., Ltd	marketed	alpha-Adrenergic Agonist	Alpha-2C adrenergic receptor	1996-01-01
Iopidine	APRACLONIDINE	Harrow Health	marketed	alpha-Adrenergic Agonist	Alpha-2A adrenergic receptor	1987-01-01
Cortone	CORTISONE ACETATE		marketed	alpha-Adrenergic Agonist [EPC]	Corticosteroid-binding globulin	1950-01-01
Bupivacaine Hydrochloride And Epinephrine	Epinephrine	Pfizer Inc.	marketed	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01
Epipen	epinephrine	Pfizer Inc.	marketed	alpha-Adrenergic Agonist [EPC]	Alpha-1D adrenergic receptor	1948-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-12-12 — Bupivacaine Hydrochloride And Epinephrine · 11590286 · Formulation · US
2026-12-12 — Epipen · 11590286 · Formulation · US
2027-02-27 — Bupivacaine Hydrochloride And Epinephrine · 8206360 · Formulation · US
2027-02-27 — Epipen · 8206360 · Formulation · US
2028-03-12 — Epipen · 7947017 · Formulation · US
2028-03-12 — Bupivacaine Hydrochloride And Epinephrine · 7947017 · Formulation · US
2028-11-25 — Epipen · 8231573 · Formulation · US
2028-11-25 — Bupivacaine Hydrochloride And Epinephrine · 8231573 · Formulation · US
2029-04-10 — Epipen · 8226610 · Formulation · US
2029-04-10 — Bupivacaine Hydrochloride And Epinephrine · 8226610 · Formulation · US
2029-11-02 — Epipen · 8021344 · Formulation · US
2029-11-02 — Bupivacaine Hydrochloride And Epinephrine · 8021344 · Formulation · US
2035-03-13 — Epipen · 12280024 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 10130592 · Formulation · US
2035-03-13 — Epipen · 9119876 · Formulation · US
2035-03-13 — Epipen · 10130592 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 9119876 · Formulation · US
2035-03-13 — Epipen · 9295657 · Method of Use · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 12280024 · Formulation · US
2035-03-13 — Bupivacaine Hydrochloride And Epinephrine · 9295657 · Method of Use · US
2036-10-20 — Epipen · 11141540 · Formulation · US
2036-10-20 — Bupivacaine Hydrochloride And Epinephrine · 11141540 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 10842938 · Formulation · US
2037-12-21 — Epipen · 10688244 · Formulation · US
2037-12-21 — Epipen · 10842938 · Formulation · US
2037-12-21 — Epipen · 11771830 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 10688244 · Formulation · US
2037-12-21 — Bupivacaine Hydrochloride And Epinephrine · 11771830 · Formulation · US
2038-02-06 — Epipen · 10576156 · Formulation · US
2038-02-06 — Bupivacaine Hydrochloride And Epinephrine · 11173209 · Method of Use · US

Sponsor landscape (alpha-Adrenergic Agonist [EPC] class)

· 2 drugs in this class
Pfizer Inc. · 2 drugs in this class
Provepharm Sas · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gaba — Competitive Intelligence Brief. https://druglandscape.com/ci/aminobutyric-acid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab